Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
BridgeBio Pharma, Inc. (BBIO)
Sector: Healthcare; Industry: Biotechnology

BridgeBio Pharma, Inc. discovers and develops various medicines for genetic diseases. In addition, it is involved in the development of; BBP-551 to treat inherited retinal disease; BBP-472 to treat autism-spectrum disorder; BBP-009/Patidegib to treat gorlin syndrome and high-frequency basal cell carcinoma; BBP-589/PTR-01 to treat recessive dystrophic epidermolysis bullosa; BBP-681 to treat venous and lymphatic malformations; BBP-561 to treat netherton syndrome; BBP-398 to treat cancer; BBP-954 to treat solid and hematological cancers; BBP-812 for canavan disease; and BBP-815 to treat nonsyndromic hearing loss.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-11-17 Kumar Neil CEO and President Sell 34,640 $9.40 $325,606 Yes
2022-11-17 STEPHENSON BRIAN C Secretary, Treasurer & CFO Sell 19,678 $9.40 $184,985 Yes
2022-03-15 Ellis Andrea Director Buy 12,000 $8.39 $100,680 No
2022-01-05 Dachille Douglas A. Director Buy 10,000 $16.36 $163,650 No
2021-12-29 SAUNDERS BRENT L Director Buy 17,600 $14.48 $254,880 No
2021-12-29 Valantine Hannah Director Buy 1,764 $14.23 $25,102 No
2021-12-29 Hassan Fred Director Buy 19,300 $14.17 $273,390 No
2021-12-29 MOMTAZEE JAMES C Director Buy 80,000 $14.50 $1,160,000 No
2021-12-30 DANIELS RONALD J Director Buy 10,402 $14.26 $148,343 No
2020-06-08 HENDERSON MICHAEL THOMAS Chief Business Officer Sell 606 $30.01 $18,185 No
2021-12-29 Hassan Fred Director Buy 19,300 $14.17 $273,390 No
2021-12-29 MOMTAZEE JAMES C Director Buy 80,000 $14.50 $1,160,000 No
2020-06-08 HENDERSON MICHAEL THOMAS Chief Business Officer Sell 606 $30.01 $18,185 No
2021-12-29 Hassan Fred Director Buy 19,300 $14.17 $273,390 No
2021-12-29 MOMTAZEE JAMES C Director Buy 80,000 $14.50 $1,160,000 No
2021-12-30 DANIELS RONALD J Director Buy 10,402 $14.26 $148,343 No
2021-08-04 SCHELLER RICHARD H Director Sell 13,777 $53.23 $733,317 Yes
2021-02-17 STEPHENSON BRIAN C nan Buy 8,000 $62.50 $500,000 Yes
2021-02-17 Scott Randal W. Director Buy 16,000 $62.50 $1,000,000 No
2021-02-17 KKR Genetic Disorder L.P. 10%-Owner Sell 3,450,000 $60.47 $208,617,360 No
2020-12-28 Turtle Cameron nan Sell 19,500 $69.60 $1,357,184 Yes
2020-12-21 SCHELLER RICHARD H Director Sell 60,401 $65.32 $3,945,137 No
2020-12-18 SCHELLER RICHARD H Director Sell 30,000 $65.07 $1,952,021 No
2020-12-15 SCHELLER RICHARD H Director Sell 31,443 $60.38 $1,898,417 Yes
2020-12-01 HENDERSON MICHAEL THOMAS Chief Business Officer Sell 10,000 $51.52 $515,204 Yes
2020-06-03 HENDERSON MICHAEL THOMAS Chief Business Officer Sell 784 $30.04 $23,549 No
2020-11-25 Turtle Cameron nan Sell 5,000 $47.04 $235,181 Yes
2020-11-16 HENDERSON MICHAEL THOMAS Chief Business Officer Sell 10,000 $45.00 $450,000 Yes
2020-11-13 MCCORMICK FRANK Chairman of Oncology Sell 100,000 $42.76 $4,275,769 No
2020-11-05 Turtle Cameron nan Sell 2,500 $42.05 $105,125 Yes

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.

Insider Smart

Ovintiv Inc (OVV) - Insiders of OVV have been HEAVILY accumulating shares in March with a sub-$3 cost. And the stock is now $11. An awesome 400% gain can't be missed if you found it was heavily accumulated earlier.